Table 1

Chemotherapy Associated With Left Ventricular Dysfunction

Chemotherapy AgentsIncidence (%)Frequency of Use
Anthracyclines
 Doxorubicin (Adriamycin) (6,7)3–26+++
 Epirubicin (Ellence) (10)0.9–3.3++
 Idarubicin (Idamycin PFS) (8)5–18+
Alkylating agents
 Cyclophosphamide (Cytoxan) (8,11–13)7–28+++
 Ifosfamide (Ifex) (8,14)17+++
Antimetabolites
 Clofarabine (Clolar) (10)27+
Antimicrotubule agents
 Docetaxel (Taxotere) (10,15,16)2.3–8++
Monoclonal antibody-based tyrosine kinase inhibitors
 Bevacizumab (Avastin) (10,18,19)1.7–3++
 Trastuzumab (Herceptin) (20–28)2–28++
Proteasome inhibitor
 Bortezomib (Velcade) (10,17)2–5++
Small molecule tyrosine kinase inhibitors
 Dasatinib (Sprycel) (10)2–4++
 Imatinib mesylate (Gleevec) (34,35)0.5–1.7+
 Lapatinib (Tykerb) (32)1.5–2.2+
 Sunitinib (Sutent) (36,37)2.7–11+++

If 5,000 doses per year were dispensed, then the agent was assigned +++; if 1,000 to 5,000 doses per year were dispensed, the agent was assigned ++; lastly, if 1,000 doses were dispensed per year, then + was assigned to correspond to its frequency of use.

  • At a cumulative dose of 550 mg/m2. Medication manufacturers (and locations): Adriamycin, Pharmacia & Upjohn SpA, Milano, Italy; Ellence, Idamycin, and Sutent, Pfizer Inc., New York, New York; Cytoxan, Ifex, and Sprycel, Bristol-Myers Squibb, Princeton, New Jersey; Clolar, Genzyme Oncology, Cambridge, Massachusetts; Taxotere, Sanofi-Aventis U.S. LLC, Bridgewater, New Jersey; Avastin and Herceptin, Genentech Inc., South San Francisco, California; Velcade, Millenium Pharmaceuticals, Cambridge, Massachusetts; Gleevac, Novartis Pharmaceuticals Corp., East Hanover, New Jersey; Tykerb, GlaxoSmithKline, Research Triangle Park, North Carolina.